Zoetis Inc. (ZTS) Stock Analysis
Recovery setup · Temp Headwind edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $79.74 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%).
Zoetis is a global animal health company selling medicines, vaccines, and diagnostics for companion animals (70% of revenue) and livestock (29%) across approximately 45 countries. US revenue was $5,097M (54%) and International $4,254M (45%) of ~$9.4B in 2025 revenue, spanning... Read more
Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $79.74 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%). Chart setup: Death cross but MACD improving, RSI 48. Score 5.6/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Zoetis Inc.
Latest news
- NEWS Here's why Zoetis (ZTS) is a strong value stock - MSN — MSN positive
- NEWS A Look At Zoetis (ZTS) Valuation As Investors Revisit The Stock After Mixed Recent Returns - Yahoo Finance — Yahoo Finance neutral
- NEWS Citi Just Made Zoetis Its Top Pick With a Buy Rating: Is the Pet Economy Boom the Best Trade of 2026? - 24/7 Wall St. — 24/7 Wall St. positive
- NEWS Massachusetts Financial Services Co. MA Acquires 126,543 Shares of Zoetis Inc. $ZTS - MarketBeat — MarketBeat neutral
- NEWS How Investors May Respond To Zoetis (ZTS) Deepening Its Biologics Focus After World Vaccine Congress Update - Yahoo Fina — Yahoo Finance positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States54%10-K Item 1: 'United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025'
- HIGHProductcompanion animal products70%10-K Item 1: 'Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025.'
- MEDIUMProducttop five product lines (Simparica/Simparica Trio, Apoquel, Cytopoint, Librela, ceftiofur)42%10-K Item 1A: 'our five top-selling products and product lines, Simparica/Simparica Trio ... contributed approximately 42% of our revenue in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $79.74 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%). Chart setup: Death cross but MACD improving, RSI 48. Prior stop was $74.70. Score 5.6/10, moderate confidence.
Take-profit target: $112.13 (+40.5% upside). Prior stop was $74.70. Stop-loss: $74.70.
Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%); Leverage penalty (D/E 2.9): -1.5.
Zoetis Inc. trades at a P/E of 13.0 (forward 10.7). TrendMatrix value score: 7.5/10. Verdict: Sell.
24 analysts cover ZTS with a consensus score of 3.8/5. Average price target: $125.
What does Zoetis Inc. do?Zoetis is a global animal health company selling medicines, vaccines, and diagnostics for companion animals (70% of...
Zoetis is a global animal health company selling medicines, vaccines, and diagnostics for companion animals (70% of revenue) and livestock (29%) across approximately 45 countries. US revenue was $5,097M (54%) and International $4,254M (45%) of ~$9.4B in 2025 revenue, spanning roughly 300 product lines under brands including Simparica, Apoquel, and Cytopoint.